STOCK TITAN

[144] USANA Health Sciences Inc SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144
Rhea-AI Filing Summary

USANA Health Sciences (USNA) filer submitted a Form 144 proposing the sale of 5,169 common shares through Morgan Stanley Smith Barney on the NYSE. The shares have an aggregate market value of $165,408 and the issuer reports 18,271,836 shares outstanding, making the sale a small fraction of total shares. The shares were acquired as restricted stock in early February 2025 (944 on 02/07/2025, 2,805 on 02/08/2025 and 1,420 on 02/06/2025) and the approximate sale date is listed as 08/28/2025. The filing includes the standard representation that the seller is not aware of undisclosed material adverse information.

Il dichiarante di USANA Health Sciences (USNA) ha depositato un Form 144 proponendo la vendita di 5.169 azioni ordinarie tramite Morgan Stanley Smith Barney sulla NYSE. Le azioni hanno un valore di mercato complessivo di 165.408 dollari e l'emittente segnala 18.271.836 azioni in circolazione, quindi la vendita rappresenta una frazione ridotta del totale. Le azioni sono state acquisite come azioni vincolate all'inizio di febbraio 2025 (944 il 07/02/2025, 2.805 il 08/02/2025 e 1.420 il 06/02/2025) e la data approssimativa di vendita è indicata come il 28/08/2025. Il deposito include la dichiarazione standard che il venditore non è a conoscenza di informazioni negative rilevanti non divulgate.

El declarante de USANA Health Sciences (USNA) presentó un Formulario 144 proponiendo la venta de 5.169 acciones ordinarias a través de Morgan Stanley Smith Barney en la NYSE. Las acciones tienen un valor de mercado agregado de 165.408 dólares y el emisor informa 18.271.836 acciones en circulación, por lo que la venta constituye una pequeña fracción del total. Las acciones se adquirieron como acciones restringidas a principios de febrero de 2025 (944 el 07/02/2025, 2.805 el 08/02/2025 y 1.420 el 06/02/2025) y la fecha aproximada de venta figura como el 28/08/2025. La presentación incluye la declaración habitual de que el vendedor no tiene conocimiento de información adversa material no divulgada.

USANA Health Sciences(USNA) 신고인은 NYSE에서 Morgan Stanley Smith Barney를 통해 보통주 5,169주 매각을 제안하는 Form 144를 제출했습니다. 해당 주식의 총 시가총액은 165,408달러이며, 발행사는 유통 주식 수를 18,271,836주로 보고해 이번 매각은 전체의 일부에 불과합니다. 주식은 2025년 2월 초 제한주로 취득되었습니다(2025-02-07에 944주, 2025-02-08에 2,805주, 2025-02-06에 1,420주)며, 예상 매각일은 2025-08-28로 기재되어 있습니다. 제출 서류에는 매도인이 공개되지 않은 중대한 불리한 정보를 인지하고 있지 않다는 통상적인 진술이 포함되어 있습니다.

Le déclarant de USANA Health Sciences (USNA) a déposé un formulaire 144 proposant la vente de 5 169 actions ordinaires via Morgan Stanley Smith Barney sur le NYSE. Les actions représentent une valeur de marché globale de 165 408 dollars et l'émetteur indique 18 271 836 actions en circulation, de sorte que la vente ne représente qu'une faible fraction du total. Les actions ont été acquises en tant qu'actions restreintes début février 2025 (944 le 07/02/2025, 2 805 le 08/02/2025 et 1 420 le 06/02/2025) et la date approximative de vente est indiquée au 28/08/2025. Le dossier inclut la déclaration standard selon laquelle le vendeur n'est pas au courant d'informations défavorables importantes non divulguées.

Der Einreicher von USANA Health Sciences (USNA) reichte ein Formular 144 ein, in dem der Verkauf von 5.169 Stammaktien über Morgan Stanley Smith Barney an der NYSE vorgeschlagen wird. Die Aktien haben einen Gesamtmarktwert von 165.408 US-Dollar, und der Emittent meldet 18.271.836 ausstehende Aktien, sodass der Verkauf nur einen geringen Bruchteil des Gesamtbestands ausmacht. Die Aktien wurden Anfang Februar 2025 als eingeschränkte Aktien erworben (944 am 07.02.2025, 2.805 am 08.02.2025 und 1.420 am 06.02.2025) und das ungefähre Verkaufsdatum ist mit dem 28.08.2025 angegeben. Die Einreichung enthält die übliche Erklärung, dass der Verkäufer sich keiner nicht offengelegten, wesentlichen nachteiligen Informationen bewusst ist.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine insider notification of a planned sale; size appears immaterial relative to shares outstanding.

The Form 144 documents a proposed disposition of 5,169 USNA common shares via Morgan Stanley Smith Barney with an aggregated value of $165,408 and an approximate sale date of August 28, 2025. The underlying shares were issued as restricted stock in early February 2025. Compared with the reported 18,271,836 shares outstanding, this represents a very small percentage of the float, indicating the filing is procedural and unlikely to have material market impact. The disclosure includes the customary attestation regarding material nonpublic information, and no other transactions in the prior three months are reported.

TL;DR: Proper Rule 144 notice for planned sale; compliance appears complete but provides limited substantive detail.

The submission lists broker details, exact share counts, acquisition dates and types (restricted stock), and attests to absence of undisclosed material information. These elements satisfy Form 144 requirements for notifying the market of a proposed sale under Rule 144. There is no indication of an adopted trading plan or 10b5-1 scheduling in the remarks, and no prior sales reported in the past three months. From a governance perspective, documentation appears routine and compliant.

Il dichiarante di USANA Health Sciences (USNA) ha depositato un Form 144 proponendo la vendita di 5.169 azioni ordinarie tramite Morgan Stanley Smith Barney sulla NYSE. Le azioni hanno un valore di mercato complessivo di 165.408 dollari e l'emittente segnala 18.271.836 azioni in circolazione, quindi la vendita rappresenta una frazione ridotta del totale. Le azioni sono state acquisite come azioni vincolate all'inizio di febbraio 2025 (944 il 07/02/2025, 2.805 il 08/02/2025 e 1.420 il 06/02/2025) e la data approssimativa di vendita è indicata come il 28/08/2025. Il deposito include la dichiarazione standard che il venditore non è a conoscenza di informazioni negative rilevanti non divulgate.

El declarante de USANA Health Sciences (USNA) presentó un Formulario 144 proponiendo la venta de 5.169 acciones ordinarias a través de Morgan Stanley Smith Barney en la NYSE. Las acciones tienen un valor de mercado agregado de 165.408 dólares y el emisor informa 18.271.836 acciones en circulación, por lo que la venta constituye una pequeña fracción del total. Las acciones se adquirieron como acciones restringidas a principios de febrero de 2025 (944 el 07/02/2025, 2.805 el 08/02/2025 y 1.420 el 06/02/2025) y la fecha aproximada de venta figura como el 28/08/2025. La presentación incluye la declaración habitual de que el vendedor no tiene conocimiento de información adversa material no divulgada.

USANA Health Sciences(USNA) 신고인은 NYSE에서 Morgan Stanley Smith Barney를 통해 보통주 5,169주 매각을 제안하는 Form 144를 제출했습니다. 해당 주식의 총 시가총액은 165,408달러이며, 발행사는 유통 주식 수를 18,271,836주로 보고해 이번 매각은 전체의 일부에 불과합니다. 주식은 2025년 2월 초 제한주로 취득되었습니다(2025-02-07에 944주, 2025-02-08에 2,805주, 2025-02-06에 1,420주)며, 예상 매각일은 2025-08-28로 기재되어 있습니다. 제출 서류에는 매도인이 공개되지 않은 중대한 불리한 정보를 인지하고 있지 않다는 통상적인 진술이 포함되어 있습니다.

Le déclarant de USANA Health Sciences (USNA) a déposé un formulaire 144 proposant la vente de 5 169 actions ordinaires via Morgan Stanley Smith Barney sur le NYSE. Les actions représentent une valeur de marché globale de 165 408 dollars et l'émetteur indique 18 271 836 actions en circulation, de sorte que la vente ne représente qu'une faible fraction du total. Les actions ont été acquises en tant qu'actions restreintes début février 2025 (944 le 07/02/2025, 2 805 le 08/02/2025 et 1 420 le 06/02/2025) et la date approximative de vente est indiquée au 28/08/2025. Le dossier inclut la déclaration standard selon laquelle le vendeur n'est pas au courant d'informations défavorables importantes non divulguées.

Der Einreicher von USANA Health Sciences (USNA) reichte ein Formular 144 ein, in dem der Verkauf von 5.169 Stammaktien über Morgan Stanley Smith Barney an der NYSE vorgeschlagen wird. Die Aktien haben einen Gesamtmarktwert von 165.408 US-Dollar, und der Emittent meldet 18.271.836 ausstehende Aktien, sodass der Verkauf nur einen geringen Bruchteil des Gesamtbestands ausmacht. Die Aktien wurden Anfang Februar 2025 als eingeschränkte Aktien erworben (944 am 07.02.2025, 2.805 am 08.02.2025 und 1.420 am 06.02.2025) und das ungefähre Verkaufsdatum ist mit dem 28.08.2025 angegeben. Die Einreichung enthält die übliche Erklärung, dass der Verkäufer sich keiner nicht offengelegten, wesentlichen nachteiligen Informationen bewusst ist.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does USNA's Form 144 disclose about the proposed sale?

The filing discloses a proposed sale of 5,169 common shares through Morgan Stanley Smith Barney with an aggregate market value of $165,408 and an approximate sale date of 08/28/2025.

How many USNA shares are outstanding according to the filing?

The Form 144 reports 18,271,836 shares outstanding.

When and how were the shares being sold acquired?

The shares were acquired as restricted stock from the issuer on 02/06/2025, 02/07/2025, and 02/08/2025 totaling 5,169 shares.

Was any sale of USNA securities reported in the past three months?

No. The filing states Nothing to Report for securities sold during the past three months by the person for whose account the securities will be sold.

Which broker is handling the proposed sale of USNA shares?

The broker listed is Morgan Stanley Smith Barney LLC Executive Financial Services located at 1 New York Plaza, 8th Floor, New York, NY 10004.
Usana Health Sciences Inc

NYSE:USNA

USNA Rankings

USNA Latest News

USNA Latest SEC Filings

USNA Stock Data

586.71M
10.41M
42.93%
61.14%
4.03%
Packaged Foods
Medicinal Chemicals & Botanical Products
Link
United States
SALT LAKE CITY